New anti-cancer role for PDK1 inhibitors: Preventing resistance to tamoxifen

Biochemical Journal

Volumn 417, Issue 1, 2009, Pages

  Peifer, Christian ^a   Alessi, Dario R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Akt; Growth factor signalling pathway; Phosphoinositide 3 kinase (PI3K); Phosphoinositide dependent kinase 1 (PDK1); Tamoxifen sensitization

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; AMIODARONE; FENBENDAZOLE; FULVESTRANT; LEVOMEPROMAZINE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; S6 KINASE; SERTRALINE; TAMOXIFEN; THIORIDAZINE; TRICIRIBINE; UNCLASSIFIED DRUG; ANTIESTROGEN; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL TRANSFERRING) KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE;

BREAST CANCER; CANCER RESISTANCE; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

MAMMALIA;

CELL LINE, TUMOR; CELL SURVIVAL; ESTROGEN ANTAGONISTS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 58249092754     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20082243     Document Type: Note

References (19)

1. Iorns, E., Lord, C. J. and Ashworth, A. (2008) Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitisation. Biochem. J. 417, 361-370
2. Mora, A., Komander, D., Van Aalten, D. M. and Alessi, D. R. (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161-170
3. Yuan, T. L. and Cantley, L. C. (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510
4. Zeng, X., Xu, H. and Glazer, R. I. (2002) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Cα. Cancer Res. 62, 3538-3543
5. +/-. mice. Curr. Biol. 15, 1839-1846
6. Guertin, D. A. and Sabatini, D. M. (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9-22
7. Garcia-Echeverria, C. and Sellers, W. R. (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511-5526
8. Barnett, S. F., Defeo-Jones, D., Fu, S., Hancock, P. J., Haskell, K. M., Jones, R. E., Kahana, J. A., Kral, A. M., Leander, K., Lee, L. L. et al. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399-408
9. Green, C. J., Goransson, O., Kular, G. S., Leslie, N. R., Gray, A., Alessi, D. R., Sakamoto, K. and Hundal, H. S. (2008) Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J. Biol. Chem. 283, 27653-27667
10. Sabnis, G., Goloubeva, O., Jelovac, D., Schayowitz, A. and Brodie, A. (2007) Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin. Cancer Res. 13, 2751-2757
11. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S. and Nakshatri, H. (2001) Phosphatidylinositol 3-kinase/ AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817-9824
12. Accili, D. and Arden, K. C. (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421-426
13. Lengyel, F., Vertes, Z., Kovacs, K. A., Kornyei, J. L., Sumegi, B. and Vertes, M. (2007) Effect of estrogen and inhibition of phosphatidylinositol-3 kinase on Akt and FOXO1 in rat uterus. Steroids 72, 422-428
14. Chen, F. L., Xia, W. and Spector, N. L. (2008) Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin. Cancer Res. 14, 6730-6734
15. Buschbeck, M. (2006) Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer. Drugs R D 7, 73-86
16. Eichhorn, P. J., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R. and Baselga, J. (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68, 9221-9230
17. Elia, U. and Flescher, E. (2008) PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells. Neoplasia 10, 1303-1313
18. Riedel, R. F., Porrello, A., Pontzer, E., Chenette, E. J., Hsu, D. S., Balakumaran, B., Potti, A., Nevins, J. and Febbo, P. G. (2008) A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol. Cancer Ther. 7, 3141-3149
19. Peifer, C. and Alessi, D. R. (2008) Small-molecule inhibitors of PDK1. ChemMedChem, doi: 10.1002/cmdc.200800195